What is Tango Therapeutics's D&A?

Tango Therapeutics (TNGX) reported D&A of $463K in Q1 2026.

How has Tango Therapeutics's D&A changed year-over-year?

Tango Therapeutics's D&A decreased by 25.6% year-over-year, from $622K to $463K.

What is the long-term trend for Tango Therapeutics's D&A?

Over 4 years (2021 to 2025), Tango Therapeutics's D&A has grown at a 27.2% compound annual growth rate (CAGR), from $872K to $2.28M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Tango Therapeutics TNGX D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

AmgenAMGN

$1.12B-19.5%

ExelixisEXEL

$6.95M-5.4%

Cogent Biosciences, Inc.COGT

$626K-2.2%

CG OncologyCGON

$841K+3,404%

Lantheus HoldingsLNTH

$22.68M+66.5%

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's D&A?: Tango Therapeutics (TNGX) reported D&A of $463K in Q1 2026.
How has Tango Therapeutics's D&A changed year-over-year?: Tango Therapeutics's D&A decreased by 25.6% year-over-year, from $622K to $463K.
What is the long-term trend for Tango Therapeutics's D&A?: Over 4 years (2021 to 2025), Tango Therapeutics's D&A has grown at a 27.2% compound annual growth rate (CAGR), from $872K to $2.28M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.